Dr. Sowmya Viswanathan

Affiliate Scientist at the Krembil Research Institute, University Health Network; Assistant Professor at the Institute of Biomaterials and Biomedical Engineering, University of Toronto

Dr. Sowmya Viswanathan is an Affiliate Scientist at the Krembil Research Institute, University Health Network, and an Assistant Professor at the Institute of Biomaterials and Biomedical Engineering and at the Department of Medicine of the University of Toronto. Her research is focused on developing anti-inflammatory cell-based therapies including next generation mesenchymal stromal cell (MSC) therapies and immunotherapies. Her lab is also focused on bioprocess optimization and translation of these cell-based therapies into clinical investigations. Dr. Viswanathan is a co-Principal Investigator of a recently completed trial using MSCs to treat osteoarthritis patients, a Canadian first. Dr. Viswanathan serves on several committees at the International Society for Cell and Gene Therapy (ISCT) including the MSC committee and the North American Legal and Regulatory Affairs Committee. She was recently appointed Associate Editor of Cytotherapy, the official journal for ISCT. Dr. Viswanathan chairs a Cell Therapy Stakeholder Group that has bilateral policy discussions with Health Canada. She is a founding member, and team leader of the Manufacturing Committee of CellCAN. She represents Canada at the International Standards Organization (ISO TC276) developing standards on Analytical Methods and Bioprocessing, for Cell and Gene therapies. She is a Regulatory and Manufacturing advisor to the Ontario Institute for Regenerative Medicine.
 

Enhancing Canine Adipose Mesenchymal Stromal Cells for Treatment of Osteoarthritis

Tuesday, September 10, 9:30 AM – 10:00 AM

 

My talk will focus on the results from our human clinical trials using bone marrow-derived mesenchymal stromal cells, and the results from this trial. I will also briefly discuss our proprietary technology to enhance the anti-inflammatory and immunomodulatory properties of MSCs and how we have been adapting this to canine MSCs with the hopes of testing them in domestic dogs with dysplasia with Dr. Koch.